



# Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis

21/11/2024 20:28:40

## Main Information

**Primary registry identifying number**

LBCTR2023015151

**Protocol number**

CLOU064C12301

**MOH registration number**

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify**

**Type of registration**

Prospective

**Type of registration: Justify**

N/A

**Date of registration in national regulatory agency**

**Primary sponsor**

Novartis Pharma AG

**Primary sponsor: Country of origin**

Novartis Pharma AG

**Date of registration in primary registry**

13/09/2023

**Date of registration in national regulatory agency**

**Public title**

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis

**Acronym**

**Scientific title**

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

**Acronym**

**Brief summary of the study: English**

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis

**Brief summary of the study: Arabic**

مقارنة فعالية وسلامة دواء ريمبروتينيبي مقابل دواء تيريفلونوميدي لدى مشاركين مصابين بالتصلب المتعدد الانتكاسي

**Health conditions/problem studied: Specify**

Relapsing Multiple Sclerosis

**Interventions: Specify**

Drug: Remibrutinib  
tablet taken orally  
Other Name: LOU064

Drug: Teriflunomide  
capsule taken orally

**Key inclusion and exclusion criteria: Inclusion criteria**

- 18 to 55 years of age
- Diagnosis of RMS according to the 2017 McDonald diagnostic criteria





- At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd) enhancing lesion in the 12 months.
- EDSS score of 0 to 5.5 (inclusive)
- Neurologically stable within 1 month

Inclusion to Extension part:

- Patients who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply

**Key inclusion and exclusion criteria: Gender**

Both

**Key inclusion and exclusion criteria: Specify gender**

**Key inclusion and exclusion criteria: Age minimum**

18

**Key inclusion and exclusion criteria: Age maximum**

55

**Key inclusion and exclusion criteria: Exclusion criteria**

- Diagnosis of primary progressive multiple sclerosis (PPMS)
- Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
- History of clinically significant CNS disease other than MS
- Ongoing substance abuse (drug or alcohol)
- History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
- Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
- Suicidal ideation or behavior
- Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
- Participants who have had a splenectomy
- Active clinically significant systemic bacterial, viral, parasitic or fungal infections
- Positive results for syphilis or tuberculosis testing
- Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
- Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
- Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
- History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or participants with moderate or severe hepatic impairment (Child-Pugh class C) or any chronic liver or biliary disease.
- History of severe renal disease or creatinine level
- Participants at risk of developing or having reactivation of hepatitis
- Hematology parameters at screening:
  - Hemoglobin: < 10 g/dl (<100g/L)
  - Platelets: < 100000/mm<sup>3</sup> (<100 x 10<sup>9</sup>/L)
  - Absolute lymphocyte count < 800/mm<sup>3</sup> (<0.8 x 10<sup>9</sup>/L)
  - White blood cells: <3 000/mm<sup>3</sup> (<3.0 x 10<sup>9</sup>/L)
  - Neutrophils: < 1 500/mm<sup>3</sup> (<1.5 x 10<sup>9</sup>/L)
  - B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
- History or current diagnosis of significant ECG abnormalities
- Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment (prior to randomization)
- Use of other investigational drugs
- Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
- History of gastrointestinal bleeding
- Major surgery within 8 weeks prior to screening
- History of hypersensitivity to any of the study drugs or excipients
- Pregnant or nursing (lactating) female participants, prior to randomization
- Women of childbearing potential not using highly effective contraception
- Sexually active males not agreeing to use condom
- Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
- Use of strong CYP3A4 inhibitors or strong CYP3A4 inducers within two weeks prior to randomization

Other inclusion and exclusion criteria may apply

**Type of study**

Interventional

**Type of intervention**

Pharmaceutical

**Type of intervention: Specify type**

N/A

**Trial scope**

Therapy

**Trial scope: Specify scope**

N/A

**Study design: Allocation**

Randomized controlled trial

**Study design: Masking**

Blinded (masking used)

**Study design: Control**

Active

**Study phase**

3

**Study design: Purpose**

Treatment

**Study design: Specify purpose**

N/A

**Study design: Assignment**

Parallel

**Study design: Specify assignment**

N/A

**IMP has market authorization**

No

**IMP has market authorization: Specify****Name of IMP**

Remibrutinib

**Year of authorization****Month of authorization****Type of IMP**

Immunological

**Pharmaceutical class**

Bruton's Tyrosine Kinase (BTK) Inhibitor

**Therapeutic indication**

Relapsing Multiple Sclerosis

**Therapeutic benefit**

Treatment

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration****Target follow-up duration: Unit****Number of groups/cohorts****Biospecimen retention****Biospecimen description**



Samples with DNA\*\*

Samples will be shipped to Q2 solutions central lab

**Target sample size**

16

**Actual enrollment target size**

**Date of first enrollment: Type**

Anticipated

**Date of first enrollment: Date**

01/04/2023

**Date of study closure: Type**

Anticipated

**Date of study closure: Date**

23/11/2029

**Recruitment status**

Pending

**Recruitment status: Specify**

**Date of completion**

**IPD sharing statement plan**

Yes

**IPD sharing statement description**

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com)

**Additional data URL**

<https://clinicaltrials.gov/ct2/show/record/NCT05147220?term=CLOU064C12301&draw=2&rank=1>

**Admin comments**

**Trial status**

Approved

## Secondary Identifying Numbers

| Full name of issuing authority | Secondary identifying number |
|--------------------------------|------------------------------|
| Clinicaltrials.gov             | NCT05147220                  |

## Sources of Monetary or Material Support

| Name               |
|--------------------|
| Novartis Pharma AG |



## Secondary Sponsors

Name

NA

## Contact for Public/Scientific Queries

| Contact type | Contact full name | Address    | Country | Telephone              | Email                         | Affiliation                                     |
|--------------|-------------------|------------|---------|------------------------|-------------------------------|---|
| Public       | Halim Abboud      | Beirut     | Lebanon | 009613535711           | halimabboud@hotmail.com       | Hotel Dieu De France                            |
| Scientific   | Hind Khairallah   | Sin El Fil | Lebanon | 009611512002 Ext. 271  | hind.khairallah@fattal.com.lb | Khalil Fattal et Fils s.a.l                     |
| Public       | Shawkat Beayni    | Al Chouf   | Lebanon | 009613700357           | shwokat.beayni@gmail.com      | Ain Wazein Medical Village                      |
| Public       | Aline Mourad      | Beirut     | Lebanon | 0096170472332          | aemourad@stgeorgehospital.org | Saint George Hospital University Medical Center |
| Public       | Hania Jarkass     | Beirut     | Lebanon | 009613043242           | haniahabi@hotmail.com         | Makassed General Hospital                       |
| Public       | Samia Khoury      | Beirut     | Lebanon | 009611350000 ext. 7422 | sk88@aub.edu.lb               | American University of Beirut Medical Center    |

## Centers/Hospitals Involved in the Study

| Center/Hospital name                            | Name of principles investigator | Principles investigator speciality | Ethical approval |
|---|---------------------------------|------------------------------------|------------------|
| Hotel Dieu De France                            | Halim Abboud                    | Neurology                          | Approved         |
| Ain Wazein Medical Village                      | Shawkat Beayni                  | Neurology                          | Approved         |
| Saint George Hospital University Medical Center | Aline Mourad                    | Neurology                          | Approved         |
| Makassed General Hospital                       | Hania Jarkass                   | Neurology                          | Approved         |
| American University of Beirut Medical Center    | Samia Khoury                    | Neurology                          | Approved         |



| Ethics Review                                   |               |                   |                                       |                      |
|---|---------------|-------------------|---------------------------------------|----------------------|
| Ethics approval obtained                        | Approval date | Contact name      | Contact email                         | Contact phone        |
| Hotel Dieu de France                            | 03/10/2022    | Sami Richa        | cue@usj.edu.lb                        | +9611421229          |
| Ain w Zein Medical Village                      | 11/11/2022    | Khaled Abdel Baki | Khaled.abdelbaki@awmedicalvillage.org | +9615509001 ext 2115 |
| Saint George Hospital University Medical Center | 15/12/2022    | Michel Daher      | mndaheer@stgeorgehospital.org         | +9611441733          |
| Makassed General Hospital                       | 30/11/2022    | Mariam Rajab      | Research.makassed@hotmail.com         | +9611636941          |
| American University of Beirut Medical Center    | 06/04/2023    | Rami Mahfouz      | rm11@aub.edu.lb                       | +9611350000 ext 5445 |



| Countries of Recruitment |  |
|--------------------------|--|
| Name                     |  |
| Argentina                |  |
| Belgium                  |  |
| Bulgaria                 |  |
| China                    |  |
| Croatia                  |  |
| Guatemala                |  |
| India                    |  |
| Italy                    |  |
| Latvia                   |  |
| Malaysia                 |  |
| Netherlands              |  |
| Poland                   |  |
| Russian Federation       |  |
| Slovakia                 |  |
| Spain                    |  |
| Switzerland              |  |
| United Kingdom           |  |
| United States of America |  |

| Health Conditions or Problems Studied |                          |                              |
|---------------------------------------|--------------------------|------------------------------|
| Condition                             | Code                     | Keyword                      |
| Relapsing Multiple Sclerosis          | Multiple sclerosis (G35) | Relapsing Multiple Sclerosis |



## Interventions

| Intervention  | Description   | Keyword   |
|---|---|---|
| Consenting, IMP administration, Laboratory testing, Imaging | Consenting, IMP administration, Laboratory testing, Imaging | Consenting, IMP administration, Laboratory testing, Imaging |

## Primary Outcomes

| Name  | Time Points             | Measure  |
|---|-------------------------|--|
| Annualized relapse rate (ARR) of confirmed relapses | Baseline up to 30 month | ARR is the average number of confirmed MS relapses in a year |

## Key Secondary Outcomes

| Name  | Time Points              | Measure  |
|---|--------------------------|--|
| Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) | Baseline up to 30 month  | Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months   |
| Time to 6-month confirmed disability progression (6mCDP) on EDSS                                    | Baseline up to 30 month  | Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months   |
| Annualized rate of new or enlarging T2 lesion   | Baseline up to 30 month  | Number of new/newly enlarged T2 lesions per year   |
| Neurofilament light chain (Nfl)   | Baseline up to 30 months | Neurofilament light chain (NFL) concentration in serum   |
| Number of Gd-enhancing T1 lesions per MRI scan  | Baseline up to 30 month  | Average number of Gd-enhancing T1 lesions per scan   |
| Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3)                          | Baseline up to 30 month  | Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI   |
| Time to first confirmed relapse   | Baseline up to 30 month  | Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating |
| Time to 6-month confirmed disability improvement (6mCDI) on EDSS                                    | Baseline up to 30 month  | Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months   |
| Change from baseline in the Symbol Digit Modalities Test (SDMT)                                     | Baseline up to 30 month  | Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening                          |
| Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW)          | Baseline, up to 30 month | The patient walking speed to cover 25 foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score   |
| Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT)             | Baseline up to 30 month  | The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)  |
| Time to composite 6-month confirmed disability Progression (CDP)                                    | Baseline up to 30 month  | The composite involves CDP and worsening by at least 20% in T25FW and 9HPT   |





|   |                               |  |
|---|-------------------------------|--|
| Change from Baseline in T2 lesion volume  | Baseline up to 30 month       | Change from baseline in total T2 lesion volume   |
| Change from baseline in Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS)                  | Baseline up to 30 month       | 20-item, self-administered questionnaire. Global score ranges from 0 to 100 where higher score represents greater fatigue  |
| Change from baseline in Generalized Anxiety Disorder Scale (GAD-7)  | Baseline up to 30 month       | 7-item, self-administered scale. It has a global score ranging from 0-21. Higher score means higher severity of anxiety symptoms   |
| Change from baseline in Patient Health Questionnaire-9 (PHQ-9)  | Baseline up to 30 month       | 9-item, self-administered scale. Scores can range from 0 to 27. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively   |
| Change from baseline in Brief Pain Inventory- short form (BPI -SF)  | Baseline up to 30 month       | 15-item, self-administered questionnaire to assess the severity of pain and the impact of pain on daily functions. Includes seven-item interference scale. It has a 10-point response option, ranging from 0 (does not interfere) to 10 (completely interferes). Global score ranges from 0 to 10, where lower scores represent lower pain |
| Change from baseline in Health Utilities Index (HUI-III)  | Baseline up to 30 month       | 15-item, self-administered index that measures eight health-related quality of life areas including vision, hearing, speech, ambulation/mobility, pain, dexterity, emotion, and cognition  |
| Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29)   | Baseline up to 30 month       | 29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life  |
| Number of participants with Adverse events and Serious adverse events(SAE)  | Baseline up to 30 month       | Adverse events and SAEs including clinically significant , laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating   |
| Pharmacokinetics of remibrutinib  | Month 1, Month 6              | Blood concentrations of remibrutinib   |
| Number of participants with Adverse events and Serious adverse events (SAE)   | Day 1 Extension up to 5 years | Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating  |
| Annualized relapse rate (ARR) of confirmed relapses [Extension Part]  | Day 1 Extension up to 5 years | ARR is the average number of confirmed MS relapses in a year   |
| Annualized rate of new or enlarging T2 lesion [Extension Part]  | Day 1 Extension up to 5 years | Number of new/newly enlarged T2 lesions per year   |
| Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]   | Day 1 Extension up to 5 years | Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months   |
| Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]  | Day 1 Extension up to 5 years | Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening        |
| Neurofilament light chain (NfL) [Extension Part]  | Day 1 Extension up to 5 years | Neurofilament light chain (NfL) concentration in serum   |
| Change from baseline in Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS) [Extension Part] | Day 1 Extension up to 5 years | 20-item, self-administered questionnaire. Global score ranges from 0 to 100 where higher score represents greater fatigue  |
| Change from baseline in Generalized Anxiety Disorder Scale (GAD-7) [Extension Part]   | Day 1 Extension up to 5 years | 7-item, self-administered scale. It has a global score ranging from 0-21. Higher score means higher severity of anxiety symptoms   |
| Change from baseline in Patient Health Questionnaire-9 (PHQ-9) [Extension Part]   | Day 1 Extension up to 5 years | 9-item, self-administered scale. Scores can range from 0 to 27. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively   |



|  |                               |  |
|--|-------------------------------|--|
| Change from baseline in Brief Pain Inventory- short form (BPI-SF) [Extension Part] | Day 1 Extension up to 5 years | 15-item, self-administered questionnaire to assess the severity of pain and the impact of pain on daily functions. Includes seven-item interference scale. It has a 10-point response option, ranging from 0 (does not interfere) to 10 (completely interferes). Global score ranges from 0 to 10, where lower scores represent lower pain |
| Change from baseline in Health Utilities Index (HUI-III) [Extension Part]          | Day 1 Extension up to 5 years | 15-item, self-administered index that measures eight health-related quality of life areas including vision, hearing, speech, ambulation/mobility, pain, dexterity, emotion, and cognition  |
| Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part] | Day 1 Extension up to 5 years | 29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life  |

## Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files

